Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

May 8, 2023

Revenue of $190.8 million, up 88% year-over-year in Q1 2023

Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023

Subscribers grew to over 1.2 million, up 87% year-over-year in Q1 2023

Raises full year 2023 revenue guidance to a range of $810 million to $830 million and Adjusted EBITDA guidance to a range of $25 million to $30 million

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the first quarter ended March 31, 2023.

“We are pleased with our outstanding performance in the first quarter, as our ability to deliver more personalized and accessible products and services is inspiring more customers to take better care of their health and well-being,” said Andrew Dudum, co-founder and CEO. “Our significant market opportunity, robust consumer demand and consistent execution across our four strategic pillars – trusted brand, leading technology, product innovation and clinical excellence – uniquely positions us as a trusted market leader.”

“Our resilient customer base and durable recurring revenue model is operating at a scale that enables us to generate high growth while generating incremental efficiencies,” said Yemi Okupe, CFO. “These dynamics enable us to unlock our market opportunity from a position of strength and we expect to continue delivering leading innovation and access to care to our customers to capitalize on our growth momentum while driving operational excellence.”

Key Business Metrics

(In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

% Change

Subscribers (end of period)

 

 

1,209

 

 

646

 

87

%

Monthly Online Revenue per Average Subscriber

 

$

55

 

$

52

 

6

%

 

 

 

 

 

 

 

Net Orders

 

 

2,047

 

 

1,207

 

70

%

AOV

 

$

90

 

$

78

 

15

%

Revenue

(In Thousands, Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

% Change

Online Revenue

 

$

184,175

 

$

94,102

 

96

%

Wholesale Revenue

 

 

6,595

 

 

7,212

 

(9

) %

Total revenue

 

$

190,770

 

$

101,314

 

88

%

First Quarter 2023 Financial Highlights

  • Revenue was $190.8 million for the first quarter of 2023 compared to $101.3 million for the first quarter of 2022, an increase of 88% year-over-year.
  • Gross margin was 80% for the first quarter of 2023 compared to 74% for the first quarter of 2022.
  • Net loss was $(10.1) million for the first quarter of 2023 compared to $(16.3) million for the first quarter of 2022.
  • Adjusted EBITDA was $6.1 million for the first quarter of 2023 compared to $(6.1) million for the first quarter of 2022.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States (“U.S. GAAP”), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers provides guidance based on current market conditions and expectations for revenue and Adjusted EBITDA, which is a non-GAAP financial measure.

For the second quarter 2023, we expect:

  • Revenue of $200 million to $205 million.
  • Adjusted EBITDA of $4 million to $7 million, reflecting an Adjusted EBITDA margin of 2% to 3%.

For the full year 2023, we expect:

  • Revenue of $810 million to $830 million.
  • Adjusted EBITDA of $25 million to $30 million, reflecting an Adjusted EBITDA margin of 3% to 4%.

The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the first quarter 2023 results on May 8, 2023, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.forhims.com/.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believe,” “estimate,” “anticipate,” “expect,” “assume,” “imply,” “intend,” “plan,” “may,” “will,” “potential,” “project,” “predict,” “continue,” “could,” or “should,” or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, our market opportunity, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our categories, our ability to innovate on and expand the scope of our offerings and experiences, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer product quality laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

As our business grows and evolves, we continually and strategically review our key metrics. Beginning with our 2022 Annual Report on Form 10-K, we commenced reporting “Subscribers” and “Monthly Online Revenue Per Average Subscriber” as additional key business metrics (as defined below). As a result of broadening the number of health and wellness categories we serve, we believe it is important to measure the holistic relationship that we have with our customers. Additionally, the recurring nature of our revenue necessitates the need for metrics that provide greater visibility into both the breadth and engagement of users on our platform. We believe Subscribers represent a more accurate reflection of the number of distinct users that we have on our platform relative to the number of subscriptions, and beginning with the three months ending March 31, 2023, we are no longer reporting “Subscriptions” as a key business metric. Monthly Online Revenue per Average Subscriber reflects how users’ engagement with products across our platform is evolving. These changes are intended to better align our key business metrics with our internal priorities and business plans.

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. We sell only non-prescription products to wholesale partners. In addition to being revenue generative and profitable, wholesale partnerships have the added benefit of generating brand awareness with new customers in physical environments.

“Subscribers” are customers who have one or more “Subscriptions”, which are agreements pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of months (for example, billed every month or every three months), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel Subscriptions in between billing periods to stop receiving additional products and services and can reactivate Subscriptions to continue receiving additional products and services.

“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

“Net Orders” are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

Average Order Value (“AOV”) is defined as Online Revenue divided by Net Orders.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share and Per Share Data, Unaudited)

 

 

 

 

 

March 31, 2023

 

December 31, 2022

 

(Unaudited)

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

48,745

 

 

$

46,772

 

Short-term investments

 

135,648

 

 

 

132,853

 

Inventory

 

20,697

 

 

 

21,562

 

Prepaid expenses and other current assets

 

20,435

 

 

 

15,408

 

Total current assets

 

225,525

 

 

 

216,595

 

Restricted cash

 

856

 

 

 

856

 

Goodwill

 

110,881

 

 

 

110,881

 

Intangibles, net

 

20,909

 

 

 

21,841

 

Operating lease right-of-use assets

 

4,548

 

 

 

4,936

 

Other long-term assets

 

13,587

 

 

 

11,232

 

Total assets

$

376,306

 

 

$

366,341

 

Liabilities and stockholders' equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

37,609

 

 

$

32,363

 

Accrued liabilities

 

14,121

 

 

 

12,448

 

Deferred revenue

 

2,866

 

 

 

1,472

 

Operating lease liabilities

 

1,687

 

 

 

1,658

 

Total current liabilities

 

56,283

 

 

 

47,941

 

Operating lease liabilities

 

3,217

 

 

 

3,649

 

Earn-out liabilities

 

3,977

 

 

 

2,975

 

Other long-term liabilities

 

84

 

 

 

35

 

Total liabilities

 

63,561

 

 

 

54,600

 

Commitments and contingencies

 

 

 

Stockholders' equity:

 

 

 

Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 200,934,421 and 200,051,689 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of March 31, 2023 and December 31, 2022

 

21

 

 

 

21

 

Additional paid-in capital

 

667,531

 

 

 

656,626

 

Accumulated other comprehensive loss

 

(111

)

 

 

(277

)

Accumulated deficit

 

(354,696

)

 

 

(344,629

)

Total stockholders' equity

 

312,745

 

 

 

311,741

 

Total liabilities and stockholders' equity

$

376,306

 

 

$

366,341

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(In Thousands, Except Share and Per Share Data, Unaudited)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Revenue

$

190,770

 

 

$

101,314

 

Cost of revenue

 

37,345

 

 

 

26,558

 

Gross profit

 

153,425

 

 

 

74,756

 

Gross margin %

 

80

%

 

 

74

%

Operating expenses:(1)

 

 

 

Marketing

 

97,245

 

 

 

48,093

 

Operations and support

 

26,182

 

 

 

15,683

 

Technology and development

 

10,748

 

 

 

6,088

 

General and administrative

 

30,513

 

 

 

21,811

 

Total operating expenses

 

164,688

 

 

 

91,675

 

Loss from operations

 

(11,263

)

 

 

(16,919

)

Other income:

 

 

 

Change in fair value of liabilities

 

(295

)

 

 

441

 

Other income, net

 

1,877

 

 

 

320

 

Total other income, net

 

1,582

 

 

 

761

 

Loss before income taxes

 

(9,681

)

 

 

(16,158

)

Provision for income taxes

 

(386

)

 

 

(94

)

Net loss

 

(10,067

)

 

 

(16,252

)

Other comprehensive income (loss)

 

166

 

 

 

(186

)

Total comprehensive loss

$

(9,901

)

 

$

(16,438

)

Net loss per share attributable to common stockholders:

 

 

 

Basic and diluted

$

(0.05

)

 

$

(0.08

)

Weighted average shares outstanding:

 

 

 

Basic and diluted

 

207,140,298

 

 

 

202,695,970

 

______________

(1)

Includes stock-based compensation expense as follows (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

Marketing

 

$

996

 

$

823

Operations and support

 

 

1,154

 

 

486

Technology and development

 

 

1,461

 

 

906

General and administrative

 

 

10,556

 

 

6,641

Total stock-based compensation expense

 

$

14,167

 

$

8,856

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands, Unaudited)

 

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Operating activities

 

 

 

Net loss

$

(10,067

)

 

$

(16,252

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

2,117

 

 

 

1,741

 

Stock-based compensation

 

14,167

 

 

 

8,856

 

Change in fair value of liabilities

 

295

 

 

 

(441

)

Net (accretion) amortization on securities

 

(1,041

)

 

 

971

 

Provision (benefit) for deferred taxes

 

49

 

 

 

(112

)

Impairment of long-lived assets

 

429

 

 

 

 

Non-cash operating lease cost

 

448

 

 

 

377

 

Non-cash acquisition-related costs

 

566

 

 

 

69

 

Non-cash other

 

75

 

 

 

(163

)

Changes in operating assets and liabilities:

 

 

 

Inventory

 

865

 

 

 

1,415

 

Prepaid expenses and other current assets

 

(4,984

)

 

 

(7,677

)

Other long-term assets

 

5

 

 

 

(30

)

Accounts payable

 

3,955

 

 

 

4,266

 

Accrued liabilities

 

1,673

 

 

 

(3,148

)

Deferred revenue

 

1,394

 

 

 

(2,043

)

Operating lease liabilities

 

(463

)

 

 

(384

)

Earn-out payable

 

 

 

 

(6,848

)

Net cash provided by (used in) operating activities

 

9,483

 

 

 

(19,403

)

Investing activities

 

 

 

Purchases of investments

 

(40,687

)

 

 

(84,881

)

Maturities of investments

 

39,084

 

 

 

82,340

 

Proceeds from sales of investments

 

 

 

 

22,291

 

Investment in website and mobile application development and internal-use software

 

(1,875

)

 

 

(1,197

)

Purchases of property, equipment, and intangible assets

 

(635

)

 

 

(100

)

Net cash (used in) provided by investing activities

 

(4,113

)

 

 

18,453

 

Financing activities

 

 

 

Proceeds from exercise of vested stock options

 

245

 

 

 

891

 

Payments for taxes related to net share settlement of equity awards

 

(3,657

)

 

 

(404

)

Payments for earn-out consideration for acquisitions

 

 

 

 

(23,014

)

Net cash used in financing activities

 

(3,412

)

 

 

(22,527

)

Foreign currency effect on cash and cash equivalents

 

15

 

 

 

(23

)

Increase (decrease) in cash, cash equivalents, and restricted cash

 

1,973

 

 

 

(23,500

)

Cash, cash equivalents, and restricted cash at beginning of period

 

47,628

 

 

 

72,640

 

Cash, cash equivalents, and restricted cash at end of period

$

49,601

 

 

$

49,140

 

Reconciliation of cash, cash equivalents, and restricted cash

 

 

 

Cash and cash equivalents

$

48,745

 

 

$

48,284

 

Restricted cash

 

856

 

 

 

856

 

Total cash, cash equivalents, and restricted cash

$

49,601

 

 

$

49,140

 

Supplemental disclosures of cash flow information

 

 

 

Cash paid for taxes

$

286

 

 

$

36

 

Non-cash investing and financing activities

 

 

 

Purchase of property and equipment included in accounts payable

$

1,290

 

 

$

 

Vesting of early exercised stock options

 

 

 

 

38

 

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), and Adjusted EBITDA margin (which is a non-GAAP ratio), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA margin to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA and Adjusted EBITDA margin to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA and Adjusted EBITDA margin is helpful to our investors as they are used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Adjusted EBITDA margin as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net loss before stock-based compensation, depreciation and amortization, acquisition-related costs (which includes consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses), impairment of long-lived assets, income taxes, change in fair value of liabilities, and interest income. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net loss and other U.S. GAAP results.

Net Loss to Adjusted EBITDA Reconciliation

(In Thousands, Unaudited)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Revenue

$

190,770

 

 

$

101,314

 

 

 

 

 

Net loss

 

(10,067

)

 

 

(16,252

)

Stock-based compensation

 

14,167

 

 

 

8,856

 

Depreciation and amortization

 

2,117

 

 

 

1,741

 

Acquisition-related costs

 

646

 

 

 

116

 

Impairment of long-lived assets

 

429

 

 

 

 

Provision for income taxes

 

386

 

 

 

94

 

Change in fair value of liabilities

 

295

 

 

 

(441

)

Interest income

 

(1,913

)

 

 

(175

)

Adjusted EBITDA

$

6,060

 

 

$

(6,061

)

 

 

 

 

Net loss as a % of revenue

 

(5

) %

 

 

(16

) %

Adjusted EBITDA margin

 

3

%

 

 

(6

) %

 

Investor Relations
Alice Lopatto
Investors@forhims.com

Media Relations
Press@forhims.com

Source: Hims & Hers Health, Inc.